Pharvaris (PHVS) Long-Term Deferred Tax (2020 - 2026)
Pharvaris' (PHVS) quarterly Long-Term Deferred Tax came in at $875169.8 in Q1 2026, up 123.46% YoY from $391638.7 in Q1 2025, and down 15.27% on a QoQ basis from $1.0 million in Q4 2025.
Analysis
Pharvaris (PHVS) Long-Term Deferred Tax (2020 - 2026) Analysis & Trends
Pharvaris (PHVS) has 7 years of Long-Term Deferred Tax data on file, last reported at $875169.8 in Q1 2026.
- Quarterly Long-Term Deferred Tax rose 123.46% year-over-year to $875169.8 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $875169.8 (up 123.46% YoY) and the FY2025 annual result came in at $1.0 million, up 95.27% from the prior year.
- Long-Term Deferred Tax declined to $875169.8 in Q1 2026, from $1.0 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $1.0 million in Q4 2025 to a low of $96667.3 in Q1 2023.
- A 5-year average of $385868.2 and a median of $337180.2 in 2025 frame the typical range for Long-Term Deferred Tax.
- Annual changes were most pronounced in 2023 — Long-Term Deferred Tax tumbled 36.97% — and 2024, when it soared 345.14%.
- Tracing PHVS's Long-Term Deferred Tax over 5 years: stood at $265063.3 in 2022, then jumped by 57.31% to $416957.9 in 2023, then increased by 21.57% to $506885.0 in 2024, then jumped by 103.78% to $1.0 million in 2025, then declined by 15.27% to $875169.8 in 2026.
- The last three Long-Term Deferred Tax figures came in at $875169.8 (Q1 2026), $1.0 million (Q4 2025), and $535260.1 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Pharvaris | 2.10 Bn | 1.73 Bn | 85,072.10 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 673.14 Bn |
| Mar 31, 2026 | 875.17 Bn |
| Dec 31, 2025 | 1,032.92 Bn |
| Sep 30, 2025 | 535,260.06 |
| Jun 30, 2025 | 337,180.23 |
| Mar 31, 2025 | 391,638.67 |
| Dec 31, 2024 | 506.89 Bn |
| Sep 30, 2024 | 267,827.18 |
| Jun 30, 2024 | 373,271.85 |
| Mar 31, 2024 | 430,304.64 |
| Dec 31, 2023 | 416.96 Bn |
| Sep 30, 2023 | 329,461.91 |
| Jun 30, 2023 | 199.83 Bn |
| Mar 31, 2023 | 96,667.31 |
| Dec 31, 2022 | 265.06 Bn |
| Sep 30, 2022 | 241,413.14 |
| Jun 30, 2022 | 106,547.74 |
| Mar 31, 2022 | 153,362.96 |
| Dec 31, 2021 | 196.82 Bn |
| Sep 30, 2021 | 138,139.36 |